cardiovascular disease
The alliance aims to benefit patients with chronic conditions and allow real-time interoperability among healthcare providers, pharmacies and payers.
The partnership will focus on software that uses ECGs to find left ventricular dysfunction and atherosclerotic cardiovascular disease.
The new product is the first to launch out of One Drop’s collaboration with pharma giant Bayer.
They will highlight the application of digital cardiac rehabilitation in cardio-oncology.
They are also seeking ways to improve high blood pressure management.
The move aims to help combat the country’s rise in type 2 diabetes and obesity.
They integrated the deep learning technology used in mechanical equipment into an ultrasound imaging device.
The AHA says future developments in health technology aimed at seniors should address this demographic’s barriers to adoption.
Published yesterday in PLoS ONE, the data suggests an alternative to the six-minute walk test often conducted in clinics to measure functional capacity.
Bayer and Exscientia will initially work on three early-stage projects using AI to speed up drug discovery.